77 related articles for article (PubMed ID: 2650085)
1. Thromboxane synthesis inhibition and renal allograft function.
Anderson C; Jendrisak M; Brunt E; Tobimatsu M; Murphy M; Sicard G; Mangino M
Transplant Proc; 1989 Feb; 21(1 Pt 1):1161-4. PubMed ID: 2650085
[TBL] [Abstract][Full Text] [Related]
2. Effects of the thromboxane synthesis inhibitor CGS-12970 on experimental acute renal allograft rejection.
Mangino MJ; Brunt EM; Von Doersten P; Anderson CB
J Pharmacol Exp Ther; 1989 Jan; 248(1):23-8. PubMed ID: 2643702
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
[TBL] [Abstract][Full Text] [Related]
4. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
5. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
Smith SR; Kubacki VB; Rakhit A; Martin LL; Schaffer AV; Jasani MK; Hefty DJ; Johnston T; Cannon C; Bennett WM
Transplantation; 1993 Dec; 56(6):1422-6. PubMed ID: 8279014
[TBL] [Abstract][Full Text] [Related]
6. Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis.
Longhofer SL; Frisbie DD; Johnson HC; Culham CA; Cooley AJ; Schultz KT; Grauer GF
Am J Vet Res; 1991 Mar; 52(3):480-7. PubMed ID: 1827969
[TBL] [Abstract][Full Text] [Related]
7. Interaction between thromboxane A2 and angiotensin II in postischemic renal vasoconstriction in dogs.
Abels BC; Branch RA; Sabra R
J Pharmacol Exp Ther; 1993 Mar; 264(3):1285-92. PubMed ID: 8450463
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclooxygenase and thromboxane synthase inhibition on the response to angiotensin II in the hypoperfused canine kidney.
Goto F; Jackson EK; Ohnishi A; Herzer W; Branch RA
J Pharmacol Exp Ther; 1987 Dec; 243(3):799-803. PubMed ID: 3121844
[TBL] [Abstract][Full Text] [Related]
9. Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate.
Perico N; Zoja C; Benigni A; Ghilardi F; Gualandris L; Remuzzi G
J Pharmacol Exp Ther; 1986 Oct; 239(1):229-35. PubMed ID: 3531461
[TBL] [Abstract][Full Text] [Related]
10. Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans.
Weir MR; Klassen DK; Hoover N; Douglas FL
J Clin Pharmacol; 1989 Dec; 29(12):1108-16. PubMed ID: 2693500
[TBL] [Abstract][Full Text] [Related]
11. Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.
Longhofer SL; Johnson HC; Culham CA; Schultz KT; Grauer GF
Am J Vet Res; 1990 Nov; 51(11):1746-50. PubMed ID: 2240799
[TBL] [Abstract][Full Text] [Related]
12. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
13. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
[TBL] [Abstract][Full Text] [Related]
14. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
Hardee MM; Moore JN; Hardee GE
Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin and thromboxane A2 moderate postischemic renal failure.
Lelcuk S; Alexander F; Kobzik L; Valeri CR; Shepro D; Hechtman HB
Surgery; 1985 Aug; 98(2):207-12. PubMed ID: 3895535
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective inhibition of thromboxane synthesis on renal function in humans.
Zipser RD
Am J Physiol; 1985 Jun; 248(6 Pt 2):F753-6. PubMed ID: 3839111
[TBL] [Abstract][Full Text] [Related]
17. Effect of verapamil on glomerular filtration rate and glomerular prostaglandin production during cyclosporine administration.
Bunke M; Wilder L
Transplantation; 1988 Dec; 46(6):919-21. PubMed ID: 3206536
[No Abstract] [Full Text] [Related]
18. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity.
Smith SR; Creech EA; Schaffer AV; Martin LL; Rakhit A; Douglas FL; Klotman PE; Coffman TM
Kidney Int; 1992 Jan; 41(1):199-205. PubMed ID: 1593856
[TBL] [Abstract][Full Text] [Related]
19. Experimental model of chronic renal allograft rejection in rats and therapeutic efficacy of a new selective thromboxane A2 (TXA2) synthetase inhibitor (CV-4151).
Tanabe K; Toma H; Sagara R; Takahashi K; Teraoka S; Ota K
Transplant Proc; 1989 Feb; 21(1 Pt 1):293-5. PubMed ID: 2650124
[No Abstract] [Full Text] [Related]
20. Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor.
Smeesters C; Chaland P; Giroux L; Moutquin JM; Etienne P; Douglas F; Corman J; St-Louis G; Daloze P
Transplant Proc; 1988 Jun; 20(3 Suppl 3):658-64. PubMed ID: 3164534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
